MedTrace Logo

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

NCT01345734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1056

Last updated 2018-12-11

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.

Conditions

Interventions

DRUG

liraglutide

Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-01
Primary Completion
2013-07-26
Completion
2013-07-26

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01345734 on ClinicalTrials.gov